A Review on Novel Therapeutic Modalities and Evidence-based Drug Treatments against Allergic Rhinitis

医学 变应原免疫治疗 重症监护医学 疾病 哮喘 模式 梅德林 生活质量(医疗保健) 鼻腔给药 过敏 免疫学 内科学 过敏原 社会科学 社会学 护理部 政治学 法学
作者
Bhupendra Kumar,Rohitas Deshmukh
出处
期刊:Current Pharmaceutical Design [Bentham Science Publishers]
卷期号:30 (12): 887-901 被引量:2
标识
DOI:10.2174/0113816128295952240306072100
摘要

Abstract: Allergic rhinitis (AR) is an IgE-mediated atopic disease that occurs due to inhaled antigens in the immediate phase. Misdiagnosis, insufficient treatment, or no treatment at all are frequent problems associated with the widespread condition known as chronic allergic rhinitis. AR symptoms include runny, itchy, stuffy, and sneezing noses. Asthma and nasal polyps, for example, sometimes occur simultaneously in patients. In order for people living with AR to be as comfortable and productive as possible, treatment should center on reducing their symptoms. The online sources and literature, such as Pubmed, ScienceDirect, and Medline, were reviewed to gather information regarding therapeutic modalities of AR and evidence-based treatments for the disease as the objectives of the present study. An increasing number of people are suffering from AR, resulting in a heavy financial and medical burden on healthcare systems around the world. Undertreating AR frequently results in a decline in quality of life. Treatment compliance is a critical challenge in the administration of AR. Innovative therapies are needed for RA to provide patients with symptom alleviation that is less expensive, more effective, and longer duration of action. Evidence-based guidelines are helpful for managing AR illness. Treating AR according to evidence-based standards can help in disease management. AR treatment includes allergen avoidance, drug therapy, immunotherapy, patient education, and follow-up. However, AR treatment with intranasal corticosteroids is more popular. Hence, in this review article, treatment options for AR are discussed in depth. We also discussed the incidence, causes, and new treatments for this clinical condition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
weixiaocuicui完成签到 ,获得积分10
2秒前
隐形曼青应助呜呼啦呼采纳,获得10
2秒前
姚运龙发布了新的文献求助10
2秒前
cbb发布了新的文献求助10
2秒前
2秒前
rain完成签到,获得积分10
3秒前
3秒前
钰钰yuyu完成签到,获得积分10
3秒前
共享精神应助LL采纳,获得10
3秒前
田様应助Jared采纳,获得10
4秒前
sirhai发布了新的文献求助30
4秒前
迷人惜萱完成签到,获得积分10
5秒前
feng应助tututu采纳,获得10
5秒前
二毛完成签到,获得积分20
5秒前
Lucas应助符昱采纳,获得10
5秒前
hhhjjjxxx完成签到,获得积分10
5秒前
贝贝发布了新的文献求助10
6秒前
呵呵呵发布了新的文献求助10
6秒前
Alice完成签到,获得积分10
6秒前
cocodudo发布了新的文献求助10
7秒前
善学以致用应助庞伟泽采纳,获得10
8秒前
复杂的连碧完成签到,获得积分20
8秒前
ccciii发布了新的文献求助10
9秒前
vivelejrlee完成签到,获得积分10
9秒前
lucky完成签到,获得积分10
9秒前
李想完成签到,获得积分10
9秒前
10秒前
10秒前
10秒前
ValarMorghulis完成签到,获得积分10
11秒前
13秒前
lucky发布了新的文献求助10
13秒前
充电宝应助caizx采纳,获得10
14秒前
14秒前
14秒前
充电宝应助ccciii采纳,获得10
15秒前
15秒前
熊涛完成签到,获得积分10
15秒前
LL发布了新的文献求助10
15秒前
高分求助中
(禁止应助)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Plutonium Handbook 4000
International Code of Nomenclature for algae, fungi, and plants (Madrid Code) (Regnum Vegetabile) 1500
Functional High Entropy Alloys and Compounds 1000
Building Quantum Computers 1000
Molecular Cloning: A Laboratory Manual (Fourth Edition) 500
Social Epistemology: The Niches for Knowledge and Ignorance 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4232531
求助须知:如何正确求助?哪些是违规求助? 3765779
关于积分的说明 11832445
捐赠科研通 3424505
什么是DOI,文献DOI怎么找? 1879328
邀请新用户注册赠送积分活动 932272
科研通“疑难数据库(出版商)”最低求助积分说明 839489